Clodronate, 1600 mg/d given orally for two years, significantly decreased the rate of bone metastases by 56 percent in women with primary breast cancer in a study presented at the 24th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR). Dr. Eugene McCloskey, with the University of Sheffield in Sheffield, UK, and colleagues, determined the effect of clodronate on the development of bone metastases, the incidence of bone metastases, and survival in women with primary operable breast cancer who had no evidence of metastases at the start of the trial. Patients were randomized to 1600 mg/d, or placebo.
Treatment was scheduled to start within six months of the patient’s primary treatment and to continue for two years. Follow-up averaged about five years. A total of 1,069 women were randomized. There were no significant differences in the baseline characeristics of the women who received clodronate or placebo, in addition to their standard treatment.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!